correlaciona-se com características anatomopatológicas de agressividade ao
diagnóstico e características de evolução clínica da doença?
Resposta: A expressão gênica e proteica de L-selectina foi menor em tumores
com locais de células de Hürthle. Além disso, a expressão proteica de L-selectina, PNAd apical e LFA-1 correlacionaram-se com características de agressividade enquanto a expressão gênica de ICAM1 e ITGAL correlacionaram-se com características de menor agressividade tumoral.
7. Conclusão
Nossos dados mostram que as moléculas de adesão celular estão expressas em células tireoidianas neoplásicas e podem desempenhar importante papel na proliferação celular. Sugerimos que, de forma geral, ocorra uma diminuição de expressão proteica dessas moléculas conforme ocorre o processo de desdiferenciação celular. Além disso, nossos achados mostram que a expressão gênica de SELL e ICAM1 e a expressão proteica de L-selectina, PNAd e LFA-1 podem auxiliar na caracterização histológica de nódulos tireoidianos de padrão folicular.
8. Referências
1. Ward LS. Thyroid tumors: are we unveiling the puzzle? Endocr Relat Cancer. 2014;21(5):E7-8.
2. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid : official journal of the American Thyroid Association. 2016;26(1):1- 133.
3. Marcello MA, Malandrino P, Almeida JF, Martins MB, Cunha LL, Bufalo NE, et al. The influence of the environment on the development of thyroid tumors: a new appraisal. Endocrine-related cancer. 2014;21(5):T235-54.
4. Society AC. Cancer Facts & Figures 2019. American Cancer Society. 2019:76. 5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34.
6. Câncer INd. Estimativa 2018: incidência de câncer no Brasil. 2018:130.
7. Curado MP, Cancer IAfRo, Edwards B, Shin HR, Ferlay J, Storm H. Cancer Incidence in Five Continents: International Agency for Research on Cancer; 2007. 8. Carling T, Udelsman R. Thyroid cancer. Annual review of medicine. 2014;65:125-37.
9. Câncer INd. Estimativa 2016: Incidência de Câncer no Brasil. Ministério da Saúde. 2016:124.
10. Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR, et al. Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009;18(4):1092-100.
11. American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, Doherty GM, Haugen BR, Kloos RT, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid : official journal of the American Thyroid Association. 2009;19(11):1167-214.
12. Rosario PW, Ward LS, Carvalho GA, Graf H, Maciel RM, Maciel LM, et al. Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus. Arquivos brasileiros de endocrinologia e metabologia. 2013;57(4):240-64.
13. Pinchera A. Thyroid incidentalomas. Horm Res. 2007;68 Suppl 5:199-201. 14. Bearhs O. Surgery of thyroid and parathyroid disorders in the aged. Surgical care for the elderly. 1988:128-37.
15. Rodrigo JP, Rinaldo A, Devaney KO, Shaha AR, Ferlito A. Molecular diagnostic methods in the diagnosis and follow-up of well-differentiated thyroid carcinoma. Head & neck. 2006;28(11):1032-9.
16. Saggiorato E, Aversa S, Deandreis D, Arecco F, Mussa A, Puligheddu B, et al. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. Journal of endocrinological investigation. 2004;27(4):311-7.
17. Ito Y, Miyauchi A, Kudo T, Oda H, Yamamoto M, Sasai H, et al. Trends in the Implementation of Active Surveillance for Low-Risk Papillary Thyroid Microcarcinomas at Kuma Hospital: Gradual Increase and Heterogeneity in the Acceptance of This New
Management Option. Thyroid : official journal of the American Thyroid Association. 2018;28(4):488-95.
18. Cunha LL, Morari EC, Guihen AC, Razolli D, Gerhard R, Nonogaki S, et al. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clinical endocrinology. 2012;77(6):918-25.
19. Cunha LL, Morari EC, Nonogaki S, Soares FA, Vassallo J, Ward LS. Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. Clinics. 2012;67(5):483-8.
20. Cunha LL, Ward LS. Concurrent lymphocytic thyroiditis is associated to less aggressive papillary thyroid carcinomas. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies. 2012;269(2):699-700.
21. Araujo PP, Marcello MA, Tincani AJ, Guilhen AC, Morari EC, Ward LS. mRNA BRAF expression helps to identify papillary thyroid carcinomas in thyroid nodules independently of the presence of BRAFV600E mutation. Pathology, research and practice. 2012;208(8):489-92.
22. Batista FA, Ward LS, Marcello MA, Martins MB, Peres KC, Torricelli C, et al. Gene expression of thyroid-specific transcription factors may help diagnose thyroid lesions but are not determinants of tumor progression. Journal of endocrinological investigation. 2016;39(4):423-9.
23. Marcello MA, Sampaio AC, Geloneze B, Vasques AC, Assumpcao LV, Ward LS. Obesity and excess protein and carbohydrate consumption are risk factors for thyroid cancer. Nutrition and cancer. 2012;64(8):1190-5.
24. Lee JH, Kim Y, Choi JW, Kim YS. The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis. European journal of endocrinology. 2013;168(3):343-9.
25. Cunha LL, Soares FA, Vassallo J, Ward LS. The role of tumor-infiltrating lymphocytes in papillary thyroid carcinomas. Journal of endocrinological investigation. 2011;34(9):733.
26. Cunha LL, Ward LS. Comments on "well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence". Endocrine pathology. 2011;22(3):172-3.
27. Kurukahvecioglu O, Taneri F, Yuksel O, Aydin A, Tezel E, Onuk E. Total thyroidectomy for the treatment of Hashimoto's thyroiditis coexisting with papillary thyroid carcinoma. Advances in therapy. 2007;24(3):510-6.
28. Elangbam CS, Qualls CW, Jr., Dahlgren RR. Cell adhesion molecules--update. Veterinary pathology. 1997;34(1):61-73.
29. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nature immunology. 2005;6(12):1182-90.
30. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678-89.
31. Gupta GS. L-Selectin (CD62L) and Its Ligands. Animal Lectins: Form, Function and Clinical Applications. Vienna: Springer Vienna; 2012. p. 553-74.
32. Raffler NA, Rivera-Nieves J, Ley K. L-selectin in inflammation, infection and immunity. Drug Discovery Today: Therapeutic Strategies. 2005;2(3):213-20.
33. Rosen SD. Ligands for L-selectin: homing, inflammation, and beyond. Annual review of immunology. 2004;22:129-56.
34. McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovascular research. 2015;107(3):331-9.
35. Rosen SD, Bertozzi CR. The selectins and their ligands. Current opinion in cell biology. 1994;6(5):663-73.
36. da Costa Martins P, van den Berk N, Ulfman LH, Koenderman L, Hordijk PL, Zwaginga JJ. Platelet-monocyte complexes support monocyte adhesion to endothelium by enhancing secondary tethering and cluster formation. Arteriosclerosis, thrombosis, and vascular biology. 2004;24(1):193-9.
37. Ivetic A, Hoskins Green HL, Hart SJ. L-selectin: A Major Regulator of Leukocyte Adhesion, Migration and Signaling. Frontiers in immunology. 2019;10:1068.
38. Kheradmand F, Werb Z. Shedding light on sheddases: role in growth and development. BioEssays : news and reviews in molecular, cellular and developmental biology. 2002;24(1):8-12.
39. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, et al. An essential role for ectodomain shedding in mammalian development. Science. 1998;282(5392):1281-4.
40. Hafezi-Moghadam A, Thomas KL, Prorock AJ, Huo Y, Ley K. L-selectin shedding regulates leukocyte recruitment. The Journal of experimental medicine. 2001;193(7):863-72.
41. Grailer JJ, Kodera M, Steeber DA. L-selectin: role in regulating homeostasis and cutaneous inflammation. Journal of dermatological science. 2009;56(3):141-7.
42. Choudhary D, Hegde P, Voznesensky O, Choudhary S, Kopsiaftis S, Claffey KP, et al. Increased expression of L-selectin (CD62L) in high-grade urothelial carcinoma: A potential marker for metastatic disease. Urologic oncology. 2015;33(9):387.e17-27.
43. Kobawala TP, Trivedi TI, Gajjar KK, Patel DH, Patel GH, Ghosh NR. Significance of TNF-alpha and the Adhesion Molecules: L-Selectin and VCAM-1 in Papillary Thyroid Carcinoma. Journal of thyroid research. 2016;2016:8143695.
44. Korniluk A, Kaminska J, Kiszlo P, Kemona H, Dymicka-Piekarska V. Lectin adhesion proteins (P-, L- and E-selectins) as biomarkers in colorectal cancer. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2017;22(7):629-34.
45. Laubli H, Borsig L. Selectins promote tumor metastasis. Seminars in cancer biology. 2010;20(3):169-77.
46. Muzza M, Degl'Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clinical endocrinology. 2010;72(5):702-8.
47. Reymond N, d'Agua BB, Ridley AJ. Crossing the endothelial barrier during metastasis. Nature reviews Cancer. 2013;13(12):858-70.
48. Kobayashi H, Boelte KC, Lin PC. Endothelial cell adhesion molecules and cancer progression. Current medicinal chemistry. 2007;14(4):377-86.
49. Borrelli N, Ugolini C, Giannini R, Antonelli A, Giordano M, Sensi E, et al. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis. Cancer cytopathology. 2016;124(5):340-9.
50. Warnock RA, Askari S, Butcher EC, von Andrian UH. Molecular mechanisms of lymphocyte homing to peripheral lymph nodes. The Journal of experimental medicine. 1998;187(2):205-16.
51. Streeter PR, Rouse BT, Butcher EC. Immunohistologic and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymph nodes. The Journal of cell biology. 1988;107(5):1853-62.
52. Kobayashi M, Mitoma J, Nakamura N, Katsuyama T, Nakayama J, Fukuda M. Induction of peripheral lymph node addressin in human gastric mucosa infected by Helicobacter pylori. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(51):17807-12.
53. Goc J, Fridman WH, Sautes-Fridman C, Dieu-Nosjean MC. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology. 2013;2(12):e26836. 54. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(27):4410-7.
55. Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, et al. Antigen- driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. Journal of immunology. 2002;169(4):1829-36.
56. Cipponi A, Mercier M, Seremet T, Baurain JF, Theate I, van den Oord J, et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer research. 2012;72(16):3997-4007.
57. Banner BF, Savas L, Baker S, Woda BA. Characterization of the inflammatory cell populations in normal colon and colonic carcinomas. Virchows Archiv B, Cell pathology including molecular pathology. 1993;64(4):213-20.
58. Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, Ditlev J, et al. Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer research. 2006;66(21):10365-76. 59. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, Luscinskas FW. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood. 2005;106(2):584-92.
60. Park S, Kang S, Veach AJ, Vedvyas Y, Zarnegar R, Kim JY, et al. Self-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions. Biomaterials. 2010;31(30):7766-75.
61. Lin YC, Shun CT, Wu MS, Chen CC. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12(23):7165-73.
62. Buitrago D, Keutgen XM, Crowley M, Filicori F, Aldailami H, Hoda R, et al. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma. Annals of surgical oncology. 2012;19(3):973-80.
63. Hayes SH, Seigel GM. Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues. International journal of clinical and experimental pathology. 2009;2(6):553-60.
64. Tanda F, Cossu A, Bosincu L, Manca A, Ibba M, Massarelli G. Intercellular adhesion molecule-1 (ICAM-1) immunoreactivity in well-differentiated thyroid papillary carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 1996;9(1):53-6.
65. Zhang KE, Ge SJ, Lin XY, Lv BB, Cao ZX, Li JM, et al. Intercellular adhesion molecule 1 is a sensitive and diagnostically useful immunohistochemical marker of papillary thyroid cancer (PTC) and of PTC-like nuclear alterations in Hashimoto's thyroiditis. Oncology letters. 2016;11(3):1722-30.
66. Laudanna C, Kim JY, Constantin G, Butcher E. Rapid leukocyte integrin activation by chemokines. Immunological reviews. 2002;186:37-46.
67. Carman CV, Springer TA. Integrin avidity regulation: are changes in affinity and conformation underemphasized? Current opinion in cell biology. 2003;15(5):547-56.
68. de Fougerolles AR, Qin X, Springer TA. Characterization of the function of intercellular adhesion molecule (ICAM)-3 and comparison with ICAM-1 and ICAM-2 in immune responses. The Journal of experimental medicine. 1994;179(2):619-29.
69. Ghislin S, Obino D, Middendorp S, Boggetto N, Alcaide-Loridan C, Deshayes F. LFA-1 and ICAM-1 expression induced during melanoma-endothelial cell co-culture favors the transendothelial migration of melanoma cell lines in vitro. BMC cancer. 2012;12:455.
70. Reina M, Espel E. Role of LFA-1 and ICAM-1 in Cancer. Cancers. 2017;9(11). 71. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nature reviews Drug discovery. 2010;9(10):804-20.
72. Lefort CT, Ley K. Neutrophil arrest by LFA-1 activation. Frontiers in immunology. 2012;3:157.
73. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annual review of physiology. 1995;57:827-72.
74. Kuwano Y, Spelten O, Zhang H, Ley K, Zarbock A. Rolling on E- or P-selectin induces the extended but not high-affinity conformation of LFA-1 in neutrophils. Blood. 2010;116(4):617-24.
75. Hwang ST, Singer MS, Giblin PA, Yednock TA, Bacon KB, Simon SI, et al. GlyCAM-1, a physiologic ligand for L-selectin, activates beta 2 integrins on naive peripheral lymphocytes. The Journal of experimental medicine. 1996;184(4):1343-8. 76. Manikwar P, Tejo BA, Shinogle H, Moore DS, Zimmerman T, Blanco F, et al. Utilization of I-domain of LFA-1 to Target Drug and Marker Molecules to Leukocytes. Theranostics. 2011;1:277-89.
77. Wang HS, Hung Y, Su CH, Peng ST, Guo YJ, Lai MC, et al. CD44 cross-linking induces integrin-mediated adhesion and transendothelial migration in breast cancer cell
line by up-regulation of LFA-1 (alpha L beta2) and VLA-4 (alpha4beta1). Experimental cell research. 2005;304(1):116-26.
78. Fujisaki T, Tanaka Y, Fujii K, Mine S, Saito K, Yamada S, et al. CD44 stimulation induces integrin-mediated adhesion of colon cancer cell lines to endothelial cells by up- regulation of integrins and c-Met and activation of integrins. Cancer research. 1999;59(17):4427-34.
79. Papas MG, Karatzas PS, Papanikolaou IS, Karamitopoulou E, Delicha EM, Adler A, et al. LFA-1 expression in a series of colorectal adenocarcinomas. Journal of gastrointestinal cancer. 2012;43(3):462-6.
80. Benedicto A, Marquez J, Herrero A, Olaso E, Kolaczkowska E, Arteta B. Decreased expression of the beta2 integrin on tumor cells is associated with a reduction in liver metastasis of colorectal cancer in mice. 2017;17(1):827.
81. Gupta GS. Selectins and Associated Adhesion Proteins in Inflammatory disorders. Animal Lectins: Form, Function and Clinical Applications. Vienna: Springer Vienna; 2012. p. 991-1026.
82. Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, et al. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer research. 2005;65(5):2009-17.
83. Yamada M, Yanaba K, Hasegawa M, Matsushita Y, Horikawa M, Komura K, et al. Regulation of local and metastatic host-mediated anti-tumour mechanisms by L- selectin and intercellular adhesion molecule-1. Clinical and experimental immunology. 2006;143(2):216-27.
84. Turner J, Rhee JG, Fabian DF, Lefor AT. Expression of ICAM-1 enhances in vivo lymphocyte adhesion in a murine fibrosarcoma. Journal of surgical oncology. 1997;66(1):39-44.
85. Eichbaum MH, de Rossi TM, Kaul S, Bastert G. Serum levels of soluble E- selectin are associated with the clinical course of metastatic disease in patients with liver metastases from breast cancer. Oncology research. 2004;14(11-12):603-10.
86. Zebrowska A, Waszczykowska E, Wagrowska-Danilewicz M, Danilewicz M, Erkiert-Polguj A, Pawliczak R, et al. Expression of selected adhesion molecules in dermatitis herpetiformis and bullous pemphigoid. Polish journal of pathology : official journal of the Polish Society of Pathologists. 2009;60(1):26-34.
87. Marazuela M, Postigo AA, Acevedo A, Diaz-Gonzalez F, Sanchez-Madrid F, de Landazuri MO. Adhesion molecules from the LFA-1/ICAM-1,3 and VLA-4/VCAM-1 pathways on T lymphocytes and vascular endothelium in Graves' and Hashimoto's thyroid glands. European journal of immunology. 1994;24(10):2483-90.
88. Nabhan F, Ringel MD. Thyroid nodules and cancer management guidelines: comparisons and controversies. Endocrine-related cancer. 2017;24(2):R13-r26.
89. Tamhane S, Gharib H. Thyroid nodule update on diagnosis and management. Clinical diabetes and endocrinology. 2016;2:17.
90. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clinical chemistry. 2009;55(4):611-22.
91. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JA. Primer3Plus, an enhanced web interface to Primer3. Nucleic acids research. 2007;35(Web Server issue):W71-4.
92. Technolgies ID. OligoAnalyzer. 2019.
93. Haeussler M, Zweig AS, Tyner C, Speir ML, Rosenbloom KR, Raney BJ, et al. The UCSC Genome Browser database: 2019 update. Nucleic acids research. 2019;47(D1):D853-D8.
94. Yates B, Braschi B, Gray KA, Seal RL, Tweedie S, Bruford EA. Genenames.org: the HGNC and VGNC resources in 2017. Nucleic Acids Res. 2017;45(D1):D619-D25. 95. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res. 2002;12(6):996-1006.
96. Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnology letters. 2004;26(6):509-15.
97. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome biology. 2002;3(7):Research0034.
98. Pfaffl MW. A new mathematical model for relative quantification in real-time RT- PCR. Nucleic acids research. 2001;29(9):e45.
99. Galdiero MR, Varricchi G, Marone G. The immune network in thyroid cancer. Oncoimmunology. 2016;5(6):e1168556.
100. Cunha LL, Marcello MA, Ward LS. The role of the inflammatory microenvironment in thyroid carcinogenesis. Endocrine-related cancer. 2014;21(3):R85- r103.
101. Cunha LL, Morari EC, Guihen AC, Razolli D, Gerhard R, Nonogaki S, et al. Infiltration of a mixture of different immune cells may be related to molecular profile of differentiated thyroid cancer. Endocrine-related cancer. 2012;19(3):L31-6.
102. Souza SL, Montalli Da Assumpcao LV, Ward LS. Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer. Thyroid : official journal of the American Thyroid Association. 2003;13(5):491-5.
103. Marcello MA, Morari EC, Cunha LL, De Nadai Silva AC, Carraro DM, Carvalho AL, et al. P53 and expression of immunological markers may identify early stage thyroid tumors. Clinical & developmental immunology. 2013;2013:846584.
104. Cunha LL, Ferreira Rde C, de Matos PS, da Assumpcao LV, Ward LS. Both gender and concurrent chronic lymphocytic thyroiditis may influence the nuclear texture of papillary thyroid carcinomas cells. Endocrine research. 2014;39(3):126-9.
105. Cunha LL, Morari EC, Nonogaki S, Marcello MA, Soares FA, Vassallo J, et al. Interleukin 10 expression is related to aggressiveness and poor prognosis of patients with thyroid cancer. Cancer immunology, immunotherapy : CII. 2017;66(2):141-8.
106. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature medicine. 2011;17(3):320-9. 107. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339(6117):286-91.
108. Huang S, Ingber DE. The structural and mechanical complexity of cell-growth control. Nature cell biology. 1999;1(5):E131-8.
109. Nair KS, Naidoo R, Chetty R. Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. Journal of clinical pathology. 2005;58(4):343-51.
110. Majchrzak-Baczmanska DB, Glowacka E, Wilczynski M, Malinowski A. Serum concentrations of soluble (s)L- and (s)P-selectins in women with ovarian cancer. Przeglad menopauzalny = Menopause review. 2018;17(1):11-7.
111. Basoglu M, Atamanalp SS, Yildirgan MI, Aydinli B, Ozturk G, Akcay F, et al. Correlation between the serum values of soluble intercellular adhesion molecule-1 and total sialic acid levels in patients with breast cancer. European surgical research
Europaische chirurgische Forschung Recherches chirurgicales europeennes. 2007;39(3):136-40.
112. Dymicka-Piekarska V, Kemona H. Does colorectal cancer clinical advancement affect adhesion molecules (sP-selectin, sE-selectin and ICAM-1) concentration? Thrombosis research. 2009;124(1):80-3.
113. Hamai A, Meslin F, Benlalam H, Jalil A, Mehrpour M, Faure F, et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer research. 2008;68(23):9854-64. 114. Nakashima M, Eguchi K, Ishikawa N, Yamashita I, Sakai M, Ida H, et al. Expression of adhesion molecule ICAM-1 (CD54) in thyroid papillary adenocarcinoma. Journal of endocrinological investigation. 1994;17(11):843-8.
115. Usami Y, Ishida K, Sato S, Kishino M, Kiryu M, Ogawa Y, et al. Intercellular adhesion molecule-1 (ICAM-1) expression correlates with oral cancer progression and induces macrophage/cancer cell adhesion. International journal of cancer. 2013;133(3):568-78.
116. Yang M, Liu J, Piao C, Shao J, Du J. ICAM-1 suppresses tumor metastasis by inhibiting macrophage M2 polarization through blockade of efferocytosis. Cell death & disease. 2015;6:e1780.
117. Maximo V, Lima J, Prazeres H, Soares P, Sobrinho-Simoes M. The biology and the genetics of Hurthle cell tumors of the thyroid. Endocrine-related cancer. 2016;23(12):X2.
118. Haznedaroglu IC, Benekli M, Ozcebe O, Savas MC, Gullu IH, Dundar SV, et al. Serum L-selectin and P-selectin levels in lymphomas. Haematologia. 2000;30(1):27-30.
119. Toppila S, Paavonen T, Nieminen MS, Hayry P, Renkonen R. Endothelial L- selectin ligands are likely to recruit lymphocytes into rejecting human heart transplants. The American journal of pathology. 1999;155(4):1303-10.
120. Lechleitner S, Kunstfeld R, Messeritsch-Fanta C, Wolff K, Petzelbauer P. Peripheral lymph node addressins are expressed on skin endothelial cells. The Journal of investigative dermatology. 1999;113(3):410-4.
121. Uchimura K, Rosen SD. Sulfated L-selectin ligands as a therapeutic target in chronic inflammation. Trends in immunology. 2006;27(12):559-65.
122. Wang B, Huang HF, Jin F, He RH. [Expressions of peripheral lymph node addressin and GlcNAc-6-sulfotransferase in endometrium and their impacts on implantation]. Beijing da xue xue bao Yi xue ban = Journal of Peking University Health sciences. 2004;36(6):575-80.
123. Ager A, May MJ. Understanding high endothelial venules: Lessons for cancer